EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor

Stephanie Schwartz, Nidhi Patel, Tyler Longmire, Pushpa Jayaraman, Xiaomo Jiang, Hongbo Lu, Lisa Baker, Janelle Velez, Radha Ramesh, Anne-Sophie Wavreille, Melanie Verneret, Hong Fan und 9 weitere

Immunotherapy Advances · 01.01.2022 · 2 (1)

DOI: 10.1093/immadv/ltac019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 10.08.2022. Verfasst von Stephanie Schwartz und 20 weiteren Autor:innen. Beteiligte Einrichtung: Immuno-Oncology and Hematology, Novartis Institutes for BioMedical Research, Cambridge, MA, USA. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Sabatolimab is a humanized monoclonal antibody (hIgG4, S228P) directed against human T-cell immunoglobulin domain and mucin domain-3 (TIM-3). Herein, we describe the development and characterization of sabatolimab.

Methods

Sabatolimab was tested for binding to its target TIM-3 and blocking properties. The functional effects of sabatolimab were tested in T-cell killing and myeloid cell cytokine assays. Antibody-mediated cell phagocytosis (ADCP) by sabatolimab was also assessed.

Results

Sabatolimab was shown to (i) enhance T-cell killing and inflammatory cytokine production by dendritic cells (DCs); (ii) facilitate the phagocytic uptake of TIM-3-expressing target cells; and (iii) block the interaction between TIM-3 and its ligands PtdSer/galectin-9.

Conclusion

Taken together, our results support both direct anti-leukemic effects and immune-mediated modulation by sabatolimab, reinforcing the notion that sabatolimab represents a novel immunotherapy with immuno-myeloid activity, holding promise for the treatment of myeloid cell neoplasms.

Autor:innen und Institutionen

  • Immuno-Oncology and Hematology, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Technical R&D GDD, Novartis Pharma Services AG., Basel, Switzerland.
  • Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Biotherapeutic and Analytical Technologies, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Oncology Translational Research, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Translational Clinical Oncology, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.

ORCID-Profile: Viviana Cremasco

Zitieren

APA

Schwartz, S., Patel, N., Longmire, T., Jayaraman, P., Jiang, X., Lu, H., Baker, L., Velez, J., Ramesh, R., Wavreille, A. S., Verneret, M., Fan, H., Hu, T., Xu, F., Taraszka, J., Pelletier, M., Miyashiro, J., Rinne, M., Dranoff, G., …, & Cremasco, V. (2022). Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Immunotherapy Advances, 2(1). https://doi.org/10.1093/immadv/ltac019

Vancouver

Schwartz S, Patel N, Longmire T, Jayaraman P, Jiang X, Lu H, et al. Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Immunotherapy Advances. 2022;2(1). doi:10.1093/immadv/ltac019

BibTeX
@article{Schwartz2022,
  author = {Schwartz, Stephanie and Patel, Nidhi and Longmire, Tyler and Jayaraman, Pushpa and Jiang, Xiaomo and Lu, Hongbo and Baker, Lisa and Velez, Janelle and Ramesh, Radha and Wavreille, Anne-Sophie and Verneret, Melanie and Fan, Hong and Hu, Tiancen and Xu, Fangmin and Taraszka, John and Pelletier, Marc and Miyashiro, Joy and Rinne, Mikael and Dranoff, Glenn and Sabatos-Peyton, Catherine and Cremasco, Viviana},
  title = {Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor},
  journal = {Immunotherapy Advances},
  year = {2022},
  volume = {2},
  number = {1},
  doi = {10.1093/immadv/ltac019}
}
Kostenlos starten →